A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

NCT04710576 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

241

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Graft-versus-host-disease

Interventions

DRUG: Axatilimab

Sponsor

Syndax Pharmaceuticals